SCYNEXIS (STU:135) Inventories, Raw Materials & Components: €0.00 Mil (As of Mar. 2026)


STU:135 SCYNEXIS Inc STU:135
43 GF Score
Price €4.84
GF Value €29.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is SCYNEXIS Inventories, Raw Materials & Components?

SCYNEXIS STU:135 43 Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:135 with a GF Score™ of 43/100 and a GF Value™ of €29.55 (Possible Value Trap). The stock has 4 warning signs investors should review.

SCYNEXIS's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €0.00 Mil.

SCYNEXIS Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Inventories, Raw Materials & Components Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.00 0.00 0.00 0.00

SCYNEXIS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:135
43GF Score
SCYNEXIS Inc STU:135
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
SCYNEXIS (STU:135) has a Inventories, Raw Materials & Components of €0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's Inventories, Raw Materials & Components too high?
SCYNEXIS's current Inventories, Raw Materials & Components is €0.00 Mil. Overall, SCYNEXIS has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Inventories, Raw Materials & Components compare to ETST and BGM?
SCYNEXIS's Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (STU:135) is currently considered Possible Value Trap. The stock's GF Value™ is €29.55, compared to a current price of €4.84 — trading 83.6% below its estimated fair value. The current Inventories, Raw Materials & Components is €0.00 Mil. SCYNEXIS's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (STU:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.84 is trading 83.6% below its estimated GF Value™ of €29.55. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for STU:135:

  • Inventories, Raw Materials & Components: €0.00 Mil
  • GF Value™: €29.55 vs. price of €4.84 (83.6% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
43GF Score

Get the complete analysis for STU:135

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84
Price
€29.55
GF Value